Archives

Pipeline

New Pipeline Updates from InflaRx, Transgene and Eli Lilly

May 20, 2019

Company Drug/Device Medical Condition Status
Tolero Pharmaceuticals, Inc. TP-3654 advanced solid tumors Phase I trial initiated
Tempest Therapeutics Inc. TPST-1120 advanced solid tumor malignancies Phase I/Ib trial initiated enrolling subjects with advanced solid tumors
ORIC Pharmaceuticals ORIC-101 in combination with nab-paclitaxel advanced solid tumors Phase Ib trial initiated
InflaRx IFX-1 ANCA-associated vasculitis (AAV) Phase II trial initiated enrolling 80 subjects at 60 sites across 12 European countries and Russia
Rigel Pharmaceuticals, Inc. fostamatinib disodium hexahydrate (fostamatinib) warm antibody autoimmune hemolytic anemia (AIHA) Phase III trial initiated enrolling 80 subjects in the U.S.
ReGenTree, LLC RGN-259 eye drops dry eye syndrome Phase III trial initiated enrolling 700 subject at 15 sites in the U.S.
Haemonetics Corporation 6s Hemostasis Analyzer System adult trauma 510(k) clearance granted by the FDA
Transgene TG4050 ovarian cancer IND approval granted by the FDA
Merz Americas XEOMIN (incobotulinumtoxinA) blepharospasm (involuntary blinking) sBLA approval granted by the FDA
AliveCor KardiaMobile 6L six-lead personal ECG device cardiovascular disease Clearance granted by the FDA
Genentech and AbbVie Venclexta (venetoclax) in combination with Gazyva (obinutuzumab) previously untreated chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) Approval granted by the FDA
EMD Serono and Pfizer, Inc. BAVENCIO (avelumab) in combination with INLYTA (axitinib) advanced renal cell carcinoma (RCC) Approval granted by the FDA
Eli Lilly and Company CYRAMZA (ramucirumab injection, 10 mg/mL solution) hepatocellular carcinoma (HCC) Approval granted by the FDA
Regeneron Pharmaceuticals, Inc. EYLEA (aflibercept) Injection diabetic retinopathy (DR) Approval granted by the FDA